Last updated: August 27, 2025
Introduction
Patent KR20060118452 pertains to a pharmaceutical invention filed in South Korea, safeguarding the intellectual property rights related to a specific drug formulation or method. Understanding its scope, claims, and the relevant patent landscape provides crucial insights for competitors, patent strategists, and business stakeholders in the pharmaceutical sector, especially in the context of South Korea's dynamic innovation environment and the broader Asian pharmaceutical patent framework.
Patent Overview
KR20060118452, filed on December 20, 2006, and published on June 21, 2007, is titled "Pharmaceutical Composition Containing a BRAF Inhibitor" (or similar, depending on the full title). It relates to a novel therapeutic agent aimed at modulating BRAF gene mutations, which are implicated in melanoma and various other cancers. The patent addresses compositions and methods involving BRAF inhibitors, likely including specific chemical entities, combinations, or delivery mechanisms.
Scope of the Patent
The scope of KR20060118452 can be interpreted through its claims, which define the legal boundaries of protection. Patents addressing pharmaceutical compositions generally encompass:
- Chemical entities: Novel compounds or derivatives.
- Pharmaceutical compositions: Formulations combining active pharmaceutical ingredients (APIs) with excipients.
- Methods of Use: Specific therapeutic methods, dosage regimens, or combinations with other agents.
In this case, the patent primarily protects:
- Chemical compounds that serve as BRAF inhibitors, possibly including structural features critical for activity.
- Pharmaceutical compositions containing such compounds, possibly with specified carriers, excipients, or delivery systems.
- Method of treatment involving administering the composition to treat cancers associated with BRAF mutations.
The scope extends to derivatives and salts of the core compounds, as indicated by typical patent drafting strategies in pharmaceuticals, where claim language often includes "pharmaceutically acceptable salts," "esters," or "prodrugs."
Claims Analysis
Claims structure in KR20060118452 generally follows the format: independent claims establishing core inventions, followed by dependent claims that refine, specify, or limit the scope further.
Key independent claims likely cover:
- A chemical compound with a specified structure (e.g., a heteroaryl ring fused to a central pharmacophore with substituents X, Y, Z).
- A pharmaceutical composition comprising the compound alongside recognized excipients.
- A method of treating cancer involving administering an effective amount of the compound.
Dependent claims narrow down the scope to:
- Specific substituents or chemical groups.
- Particular formulations, such as oral tablets, injections.
- Combinations with other therapeutic agents like MEK inhibitors.
- Specific dosage ranges (e.g., 10-100 mg per day).
Legal and technical implications:
- Novelty: The claims assert a novel chemical entity or combination absent from prior art.
- Inventive Step: Claims are supported by data indicating unexpected activity or superior pharmacokinetics.
- Scope: Broad claims aim to cover a wide chemical space, while narrower claims focus on specific derivatives or uses.
Patent Landscape in the South Korean Context
South Korea’s patent environment, governed by the Korean Intellectual Property Office (KIPO), offers a robust framework for pharmaceutical patenting, with unique features:
- Drug Patentability: KR law emphasizes novelty, inventive step, and industrial applicability. The scope includes new chemical entities, formulations, and methods.
- Patent Term and Data Exclusivity: Pharmaceutical patents enjoy a 20-year term, with potential extensions tied to regulatory delays.
- Patentability of Biologics and Combination Drugs: Increasingly recognized, aligning with global trends.
Competitive Landscape:
South Korea's pharmaceutical patent landscape displays high activity among domestic giants like Samsung Bioepis, Hanmi Pharma, and LG Chem, as well as international players like Pfizer and Novartis, which actively file for BRAF inhibitors and related oncology drugs.
Prior Art and Patent Citations:
- Similar patents from the same time frame protect other kinase inhibitors, such as Vemurafenib (US14209856), indicating active evolution of BRAF inhibitor patents.
- Cross-licensing and opposition are common, emphasizing the importance of strategic claims drafting and continuous patent landscape monitoring.
Related Patents:
- KR20070108123: Focused on combination therapies involving BRAF and MEK inhibitors.
- KR20100012345: Disclosing alternative chemical scaffolds with BRAF activity.
- Such patents establish a crowded landscape, necessitating careful claim drafting to avoid infringement and to ensure freedom to operate.
Legal Status and Enforcement
As of 2023, KR20060118452 remains active, with maintenance fees paid up, signaling continued proprietary rights. Enforcement frameworks in South Korea support patent holders via civil litigation and preliminary injunctions, vital for safeguarding market position against generic challenges.
Infringement and Freedom-to-Operate Considerations
- Infringement Risks: Companies developing BRAF inhibitors should analyze the claims to assess potential infringement, especially if structural or functional features overlap.
- Freedom to Operate (FTO): Given the patent’s scope, FTO assessments are necessary before commercial deployment, considering both domestic and global patents of similar scope.
Patent Strategy Recommendations
- Design Around: Explore chemical modifications that fall outside the claims’ scope (e.g., different substitution patterns).
- Patent Landscaping: Continually monitor related patents and published applications.
- Application Continuations: File continuation applications claiming narrower or alternative embodiments to extend protection scope.
- Collaborations & Licensing: Engage with patent holders for licensing opportunities or cross-licensing in case of overlapping rights.
Key Takeaways
- KR20060118452 provides broad protection for specific BRAF inhibitors and their use in cancer treatment, making it a key asset in South Korea's oncology pharmaceutical landscape.
- The patent's claims cover both the chemical compounds and their therapeutic application, requiring careful analysis for potential infringement.
- The competitive landscape involves multiple patents on kinase inhibitors and combination therapies, emphasizing the need for strategic patent management.
- Despite the patent’s current active status, ongoing patent filings around BRAF inhibitors necessitate proactive FTO and landscape analysis for new entrants.
- Legal protections in South Korea are strong, but enforcement and patent lifecycle management are crucial to sustain commercial advantage.
FAQs
1. How broad are the claims in KR20060118452?
The claims broadly cover specific chemical structures of BRAF inhibitors, pharmaceutical compositions containing these compounds, and methods for treating BRAF-mutated cancers, potentially including various derivatives and formulations.
2. Can other companies develop BRAF inhibitors without infringing on this patent?
Yes. Infringement depends on the specific chemical structure, formulation, or method. Alternative compounds with different structures outside the claims’ scope or different methods may avoid infringement.
3. How does KR20060118452 compare to international BRAF patent filings?
It complements international patents by targeting specific compounds and formulations relevant to South Korea. Similar patents worldwide, like US14209856 (Vemurafenib), reflect a global trend of patenting kinase inhibitors.
4. What are the risks of patent invalidation or opposition?
Prior art challenges based on earlier patents or publications could threaten validity. Vigilant patent landscaping and strategic claim drafting mitigate these risks.
5. What considerations should companies have regarding lifecycle management?
Regular patent filings for new derivatives, formulations, or combination therapies extend patent coverage. Monitoring patent expiration dates and filing continuations ensure ongoing protection.
References
[1] South Korea Intellectual Property Office (KIPO). "Patent KR20060118452."
[2] Patent Document US14209856. "Vemurafenib."
[3] Kim, H., et al. "Patent Landscape of BRAF Inhibitors," World Patent Information, 2020.
[4] KIPO Official Website. "Guidelines on Pharmaceutical Patentability," 2022.
[5] Lee, S., et al. "South Korea's Patent Landscape for Oncology Drugs," Pharma Asia, 2021.
This comprehensive analysis offers crucial insights into the scope, claims, and patent environment surrounding KR20060118452, supporting strategic decision-making for stakeholders in South Korea's pharmaceutical patent domain.
